SEC Comment Letter 0000000000-22-012636 to UroGen Pharma Ltd. (URGN) (CIK 0001668243) (URGN)
UroGen Pharma Ltd. (URGN) (CIK 0001668243)
Date: Nov. 22, 2022 · CIK: 0001668243 · Accession: 0000000000-22-012636
AI Filing Summary & Sentiment
File numbers found in text: 333-268398
Letter
United States securities and exchange commission logo November 22, 2022 Elizabeth Barrett Chief Executive Officer UroGen Pharma Ltd. 400 Alexander Park Drive, 4th Floor Princeton, NJ 08540 Re:UroGen Pharma Ltd. Registration Statement on Form S-3 Filed November 15, 2022 File No. 333-268398 Dear Elizabeth Barrett: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Charles J. Bair, Esq.
Show Raw Text
United States securities and exchange commission logo
November 22, 2022
Elizabeth Barrett
Chief Executive Officer
UroGen Pharma Ltd.
400 Alexander Park Drive, 4th Floor
Princeton, NJ 08540
Re:UroGen Pharma Ltd.
Registration Statement on Form S-3
Filed November 15, 2022
File No. 333-268398
Dear Elizabeth Barrett:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Charles J. Bair, Esq.